Executive Vice President Research, Development and Medical Affairs · ImmunoGen, Inc. (IMGN)

Michael Vasconcelles

FY2022 is the first fiscal year CompBrief holds for Michael Vasconcelles as a named executive officer of ImmunoGen; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$3,814,652

Salary $4,615Bonus $300,000

2nd of 6 named executive officers at ImmunoGen by FY2022 total.

6 named officers on file for ImmunoGen, FY2022

Michael Vasconcelles’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • IMGN’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ImmunoGen’s whole pay program stands against its peers

  • ImmunoGen’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Michael Vasconcelles’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Vasconcelles compensation by year

ImmunoGen Summary Compensation Table · the one fiscal year held
In US dollars, as ImmunoGen reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$4,615
Bonus$300,000
Option awards$3,510,032
All other$5
Total$3,814,652

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ImmunoGen, Inc. DEF 14A filed April 26, 2023, accession 0001558370-23-006874, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ImmunoGen, Inc. filed document, accession 0001558370-23-006874. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option960,000—$5.16

Per the Outstanding Equity Awards at Fiscal Year-End table in ImmunoGen, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

5 Form 4 lines since the FY2022 proxy (filed April 26, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-02-12Disposition to the issuer—1,327—0
2024-02-12Disposition to the issuer derivative—960,000—0
2024-02-12Disposition to the issuer derivative—50,515—0
2024-02-01Grant or award derivative—50,515$0.0050,515
2023-12-29Grant or award—1,327$16.011,327

The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ImmunoGen’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Mark EnyedyPresident and Chief Executive Officer$5,422,421
Michael Vasconcelles · this pageExecutive Vice President Research, Development and Medical Affairs$3,814,652
Anna BerkenblitSenior Vice President and Chief Medical Officer$1,889,484
Stacy CoenSenior Vice President and Chief Business Officer$1,838,354
Susan AltschullerFormer Senior Vice President and Chief Financial Officer$1,791,733
Renee LentiniVice President and Interim Chief Financial Officer$965,989

The full ImmunoGen compensation record

free company brief

This page is one person within ImmunoGen's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ImmunoGen proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ImmunoGen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Vasconcelles's compensation dossier · One-time report. No refunds.